Teriparatide (PTH 1-34)
Teriparatide or human recombinant parathyroid hormone (PTH 1-34) has FDA-approved labeling for the treatment of osteoporosis in postmenopausal women who are at high risk for fracture. These include women with either a history of osteoporotic fracture, have multiple risk factors for fracture, or who have failed or are intolerant to previous osteoporosis therapy. Teriparatide also has FDA-labeling for increasing bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. Unlike antiresorptive agents, teriparatide therapy stimulates new bone formation.⁴⁹